🔗 Share this article

While America undertakes sweeping changes to its immunization recommendations, one figure has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccines in the global health crisis and has concentrated on potential fatalities after Covid immunization in her recent tenure at the FDA.

Scheduled Changes to Pediatric Immunization Program

Public health authorities were set to reveal radical changes to the pediatric vaccination calendar recently, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US out of step with much of the global community with little proof for improved outcomes. The planned update has been postponed until the coming year.

Instead of Vinay Prasad, Dr. Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some childhood vaccine recommendations in the US so as to align more similar to the Danish model, a society with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – usually the domain of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

The appointee has little discernible background in drug development, approval processes or leadership, which has been typical for former directors of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a major agency. She lacks background in pharmaceutical oversight.”

Previous directors of the center would “understand regulatory frameworks and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who led the center have had.”

The drug center has an enormous range of responsibilities at the FDA, she emphasized.

“The public just focuses on the new drug program, but the off-patent medication office approves a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and every single one must be supervised,” Dr. Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a substantial administrative element to the job, which oversees over 5,000 employees. “It’s a massive leadership role, if you execute it properly,” she concluded.

Response and Disputed Programs

When asked about inquiries about Høeg’s qualifications and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a press secretary stated that the “concerns rely on inaccurate presumptions”.

“This background matches the duties of her role,” the spokesperson said, noting the months Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a disputed one-day drug-approval program that apparently troubled her predecessors. “By what process are these drugs being selected for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he said, “the FDA seems to be moving towards laxer rules of pharmaceuticals, aside from shots.”

Public Past Work on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, history, some experts have noted. She released a study using non-validated public submissions to determine the rate of heart inflammation after Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the incoming federal leadership featured changing regulations for novel immunizations and ending “optional” immunizations, she stated post-election on a podcast. At the agency, Høeg has reportedly floated the idea of preventing teenage boys from receiving COVID-19 vaccines.

“She’s an complete true believer who starts off with her conclusions and tailors the evidence to retrofit the science in a highly misleading, dishonest fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|